{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T08:48:00Z","timestamp":1763628480961,"version":"3.45.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Protein Expression and Purification"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.pep.2025.106829","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:01:46Z","timestamp":1760536906000},"page":"106829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development and expression of a factor X-derived recombinant protein for ELISA-based detection of Emicizumab"],"prefix":"10.1016","volume":"238","author":[{"given":"Sina","family":"Tavakoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohreh","family":"Zare Karizi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jafar","family":"Amani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.pep.2025.106829_bib1","first-page":"410","article-title":"Emicizumab for the treatment of acquired Hemophilia A","volume":"137","author":"Knoebl","year":"2021","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"12","key":"10.1016\/j.pep.2025.106829_bib3","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1080\/03007995.2019.1649378","article-title":"Efficacy of emicizumab prophylaxis versus Factor VIII prophylaxis for treatment of Hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial","volume":"35","author":"Reyes","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"issue":"9","key":"10.1016\/j.pep.2025.106829_bib4","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1055\/s-0039-1692427","article-title":"Laboratory monitoring in emicizumab-treated persons with Hemophilia A","volume":"119","author":"M\u00fcller","year":"2019","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.pep.2025.106829_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12725","article-title":"Quantification of emicizumab by mass spectrometry in plasma of people with Hemophilia A: a method validation study","volume":"6","author":"Donners","year":"2022","journal-title":"Res. Practice Thrombosis Haemostasis"},{"key":"10.1016\/j.pep.2025.106829_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.115163","article-title":"Development of simple and rapid method for Emicizumab quantification by LC-MS\/MS in human plasma","volume":"223","author":"Josset","year":"2023","journal-title":"J. Pharmaceut. Biomed. Anal."},{"issue":"7","key":"10.1016\/j.pep.2025.106829_bib27","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1160\/TH17-01-0030","article-title":"Factor VIIIa-mimetic cofactor activity of a bispecific antibody to Factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens","volume":"117","author":"Kitazawa","year":"2017","journal-title":"Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.pep.2025.106829_bib28","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/jth.14135","article-title":"Routine measurements of Factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti\u2010idiotype monoclonal antibodies","volume":"16","author":"Nogami","year":"2018","journal-title":"J. Thromb. Haemostasis"},{"issue":"1","key":"10.1016\/j.pep.2025.106829_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-51984-2","article-title":"Effects of codon optimization on coagulation Factor IX translation and structure: implications for protein and gene therapies","volume":"9","author":"Alexaki","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.pep.2025.106829_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/0471250953.bi0508s52","article-title":"Protein structure and function prediction using ITASSER","volume":"52","author":"Yang","year":"2015","journal-title":"Current Protocol. Bioinformat."},{"issue":"6","key":"10.1016\/j.pep.2025.106829_bib7","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.hoc.2021.07.006","article-title":"Hemophilia A (factor VIII deficiency)","volume":"35","author":"Seaman","year":"2021","journal-title":"Hematol.\/Oncol. Clin."},{"issue":"9","key":"10.1016\/j.pep.2025.106829_bib8","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/14712598.2022.2002842","article-title":"Hemophilia A gene therapy: current and next-generation approaches","volume":"22","author":"Pipe","year":"2022","journal-title":"Expet Opin. Biol. Ther."},{"issue":"9","key":"10.1016\/j.pep.2025.106829_bib9","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3324\/haematol.2019.221093","article-title":"Hemophilia A and B: molecular and clinical similarities and differences","volume":"104","author":"Castaman","year":"2019","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.pep.2025.106829_bib10","first-page":"2463","article-title":"Emicizumab, a bispecific antibody recognizing coagulation Factors IX and X: how does it actually compare to Factor VIII?","volume":"130","author":"Lenting","year":"2017","journal-title":"Blood J. Am. So. Hematol."},{"key":"10.1016\/j.pep.2025.106829_bib11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.thromres.2024.03.030","article-title":"The emicizumab-bridged ternary complex with activated Factor IX and factor X evaluated by fluorescence resonance energy transfer","volume":"237","author":"Oda","year":"2024","journal-title":"Thromb. Res."},{"issue":"6","key":"10.1016\/j.pep.2025.106829_bib2","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol."},{"issue":"9","key":"10.1016\/j.pep.2025.106829_bib12","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have Hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pep.2025.106829_bib13","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2018-99-118153","article-title":"Emicizumab prophylaxis provides flexible and effective bleed control in children with Hemophilia \u0391 with inhibitors: results from the HAVEN 2 study","volume":"132","author":"Young","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.pep.2025.106829_bib14","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in Hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.pep.2025.106829_bib15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1177\/2040620718799997","article-title":"The role of emicizumab, a bispecific Factor IXa-and Factor X-directed antibody, for the prevention of bleeding episodes in patients with Hemophilia A","volume":"9","author":"Knight","year":"2018","journal-title":"Therapeutic Adv. Hematol."},{"issue":"2","key":"10.1016\/j.pep.2025.106829_bib16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11239-021-02458-8","article-title":"Roles of Factor Xa beyond coagulation","volume":"52","author":"Ruf","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.pep.2025.106829_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtbi.2024.111757","article-title":"Kinetics and regulation of coagulation Factor X activation by intrinsic tenase on phospholipid membranes","volume":"582","author":"Sveshnikova","year":"2024","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.pep.2025.106829_bib18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jtbi.2017.09.015","article-title":"Substrate delivery mechanism and the role of membrane curvature in Factor X activation by extrinsic tenase","volume":"435","author":"Kovalenko","year":"2017","journal-title":"J. Theor. Biol."},{"issue":"6","key":"10.1016\/j.pep.2025.106829_bib19","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.hoc.2021.07.010","article-title":"Rare coagulation factor deficiencies (Factors VII, X, V, and II)","volume":"35","author":"Batsuli","year":"2021","journal-title":"Hematol.\/Oncol. Clin."},{"issue":"2","key":"10.1016\/j.pep.2025.106829_bib20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.1985.tb02990.x","article-title":"Heterogeneity of hereditary and acquired Factor X deficiencies by combined immunochemical and functional analyses","volume":"59","author":"Fair","year":"1985","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.pep.2025.106829_bib21","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/hae.14223","article-title":"Occurrence and management of severe bleeding episodes in patients with hereditary Factor X deficiency","volume":"27","author":"Tarantino","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.pep.2025.106829_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100833","article-title":"Diagnosis, therapeutic advances, and key recommendations for the management of Factor X deficiency","volume":"50","author":"Peyvandi","year":"2021","journal-title":"Blood Rev."},{"issue":"2","key":"10.1016\/j.pep.2025.106829_bib23","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11239-021-02456-w","article-title":"Blood coagulation Factor X: molecular biology, inherited disease, and engineered therapeutics","volume":"52","author":"Camire","year":"2021","journal-title":"J. Thromb. Thrombolysis"}],"container-title":["Protein Expression and Purification"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1046592825001718?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1046592825001718?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T08:45:58Z","timestamp":1763628358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1046592825001718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":27,"alternative-id":["S1046592825001718"],"URL":"https:\/\/doi.org\/10.1016\/j.pep.2025.106829","relation":{},"ISSN":["1046-5928"],"issn-type":[{"type":"print","value":"1046-5928"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and expression of a factor X-derived recombinant protein for ELISA-based detection of Emicizumab","name":"articletitle","label":"Article Title"},{"value":"Protein Expression and Purification","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pep.2025.106829","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106829"}}